Archer Materials Limited (AU:AXE) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Archer Materials is making strides in advancing its Biochip technology, focusing on improving the accuracy of graphene field effect transistor sensors for blood potassium testing, crucial for chronic kidney disease diagnosis. By refining sensor operations and design, Archer aims to enhance test precision significantly, with recent experiments showing a tenfold improvement in measurement repeatability. This development could revolutionize home diagnostics and patient outcomes by enabling more accurate and accessible chronic kidney disease testing.
For further insights into AU:AXE stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Here Is a Look into the Boeing (NYSE:BA) Contract Offers That Ended Its Strike
- What If Elon Musk Actually Did Buy the Comcast (NASDAQ:CMCSA) Channels?
- Long John Silver: Pirate, Mutineer, and Personal Finance Guru?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
